{"name":"LEO PHARMA AS","slug":"leo-pharma-as","ticker":"","exchange":"","domain":"leopharmaas.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1995-01-01","label":"Azelex first approved","drug":"Azelex","drugSlug":"azelaic-acid","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Adbry first approved","drug":"Adbry","drugSlug":"tralokinumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-18","label":"Azelex patent expiry (Formulation)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"},{"date":"2027-10-18","label":"Azelex patent expiry (Formulation)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-08","label":"Azelex patent expiry (Formulation)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-28","label":"Azelex patent expiry (Method of Use)","drug":"Azelex","drugSlug":"azelaic-acid","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Adbry","genericName":"TRALOKINUMAB","slug":"tralokinumab","indication":"Moderate to severe atopic dermatitis","status":"marketed"},{"name":"Azelex","genericName":"AZELAIC ACID","slug":"azelaic-acid","indication":"Acne vulgaris","status":"marketed"}]}],"pipeline":[{"name":"Adbry","genericName":"TRALOKINUMAB","slug":"tralokinumab","phase":"marketed","mechanism":"Adbry blocks the action of IL-13, a protein that contributes to inflammation and skin barrier disruption in atopic dermatitis.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"Azelex","genericName":"AZELAIC ACID","slug":"azelaic-acid","phase":"marketed","mechanism":"Azelex works by inhibiting the enzyme 3-oxo-5-alpha-steroid 4-dehydrogenase 2, which is involved in the production of androgens that contribute to acne and rosacea.","indications":["Acne vulgaris","Rosacea"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"7700076","type":"Formulation","expiryDate":"2027-09-18","territory":"US","genericFilings":[]},{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"10117812","type":"Formulation","expiryDate":"2027-10-18","territory":"US","genericFilings":[]},{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"9265725","type":"Formulation","expiryDate":"2027-12-08","territory":"US","genericFilings":[]},{"drugName":"Azelex","drugSlug":"azelaic-acid","patentNumber":"9211259","type":"Method of Use","expiryDate":"2029-02-28","territory":"US","genericFilings":[]}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}